These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 2530473)

  • 1. Behavioral evaluation of the anti-excitotoxic properties of MK-801: comparison with neurochemical measurements.
    Susel Z; Engber TM; Chase TN
    Neurosci Lett; 1989 Sep; 104(1-2):125-9. PubMed ID: 2530473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of MK-801, kynurenate, glycine, dextrorphan and 4-acetylpyridine on striatal toxicity of quinolinate.
    Zhu SG; McGeer EG; McGeer PL
    Brain Res; 1989 Mar; 481(2):356-60. PubMed ID: 2524238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dextromethorphan does not protect against quinolinic acid neurotoxicity in rat striatum.
    Engber TM; Chase TN
    Neurosci Lett; 1988 Dec; 95(1-3):269-74. PubMed ID: 2976130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolonged infusion of quinolinic acid into rat striatum as an excitotoxic model of neurodegenerative disease.
    Susel Z; Engber TM; Kuo S; Chase TN
    Neurosci Lett; 1991 Jan; 121(1-2):234-8. PubMed ID: 1826944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurotoxicity induced by continuous infusion of quinolinic acid into the lateral ventricle in rats.
    Yamada K; Fuji K; Nabeshima T; Kameyama T
    Neurosci Lett; 1990 Oct; 118(1):128-31. PubMed ID: 2147984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroprotective effects of MK-801 in vivo: selectivity and evidence for delayed degeneration mediated by NMDA receptor activation.
    Foster AC; Gill R; Woodruff GN
    J Neurosci; 1988 Dec; 8(12):4745-54. PubMed ID: 2904493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic treatments with GM1 ganglioside reduce quinolinic acid-induced striatal lesions in the rat.
    Lombardi G; Zanoni R; Moroni F
    Eur J Pharmacol; 1989 Dec; 174(1):123-5. PubMed ID: 2612575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CGS-19755 and MK-801 selectively prevent rat striatal cholinergic and gabaergic neuronal degeneration induced by N-methyl-D-aspartate and ibotenate in vivo.
    Schoepp DD; Salhoff CR; Hillman CC; Ornstein PL
    J Neural Transm Gen Sect; 1989; 78(3):183-93. PubMed ID: 2553073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic approaches to modifying quinolinic acid striatal lesions in rats.
    Beal MF; Kowall NW; Swartz KJ; Ferrante RJ; Martin JB
    J Neurosci; 1988 Oct; 8(10):3901-8. PubMed ID: 2461437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Idebenone attenuates neuronal degeneration induced by intrastriatal injection of excitotoxins.
    Miyamoto M; Coyle JT
    Exp Neurol; 1990 Apr; 108(1):38-45. PubMed ID: 2138566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic treatment with MK-801 increases the quinolinic acid-induced loss of D-1 dopamine receptors in rat striatum.
    Norman AB; Ford LM; Kolmonpunporn M; Sanberg PR
    Eur J Pharmacol; 1990 Feb; 176(3):363-6. PubMed ID: 2139415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intrastriatal infusion of nerve growth factor after quinolinic acid prevents reduction of cellular expression of choline acetyltransferase messenger RNA and trkA messenger RNA, but not glutamate decarboxylase messenger RNA.
    Venero JL; Beck KD; Hefti F
    Neuroscience; 1994 Jul; 61(2):257-68. PubMed ID: 7969907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tetrahydroaminoacridine potentiates neurotoxicity of quinolinic acid in rat striatum.
    Zhu SG; McGeer EG; Singh EA; McGeer PL
    Neurosci Lett; 1988 Dec; 95(1-3):252-6. PubMed ID: 2976129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lamotrigine protects against kainate but not ibotenate lesions in rat striatum.
    McGeer EG; Zhu SG
    Neurosci Lett; 1990 May; 112(2-3):348-51. PubMed ID: 2141673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential loss of neurochemical markers following quinolinic acid-induced lesions of rat striatum.
    Norman AB; Ford LM; Sanberg PR
    Exp Neurol; 1991 Oct; 114(1):132-5. PubMed ID: 1680744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential effects of insulin on choline acetyltransferase and glutamic acid decarboxylase activities in neuron-rich striatal cultures.
    Brass BJ; Nonner D; Barrett JN
    J Neurochem; 1992 Aug; 59(2):415-24. PubMed ID: 1629717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Striatal implants of fetal striatum or gelfoam protect against quinolinic acid lesions of the striatum.
    Pearlman S; Levivier M; Gash DM
    Brain Res; 1993 Jun; 613(2):203-11. PubMed ID: 8186968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The IGF-I amino-terminal tripeptide glycine-proline-glutamate (GPE) is neuroprotective to striatum in the quinolinic acid lesion animal model of Huntington's disease.
    Alexi T; Hughes PE; van Roon-Mom WM; Faull RL; Williams CE; Clark RG; Gluckman PD
    Exp Neurol; 1999 Sep; 159(1):84-97. PubMed ID: 10486177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective effect of probenecid on circling behavior of rats with unilateral quinollinic acid induced striatal lesions.
    Kravzov J; Santamaria A; Rios C; Flores A; Altagracia M
    Proc West Pharmacol Soc; 1993; 36():255-7. PubMed ID: 8378385
    [No Abstract]   [Full Text] [Related]  

  • 20. The response of striatal neuropeptide Y and cholinergic neurons to excitatory amino acid agonists.
    Boegman RJ; Parent A
    Brain Res; 1988 Jun; 452(1-2):219-26. PubMed ID: 2900050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.